Guardant Health Gross Margin 2017-2024 | GH

Guardant Health gross margin for the quarter ending September 30, 2024 was 60.49%.

  • Guardant Health average gross margin for 2023 was 61.36%, a 8.21% decline from 2022.
  • Guardant Health average gross margin for 2022 was 66.85%, a 0.8% decline from 2021.
  • Guardant Health average gross margin for 2021 was 66.32%, a 2.1% increase from 2020.

Gross margin can be defined as a company's total sales revenue minus its cost of goods sold, divided by the total sales revenue, expressed as a percentage.

Guardant Health Gross Margin 2017-2024 | GH

  • Guardant Health average gross margin for 2023 was 61.36%, a 8.21% decline from 2022.
  • Guardant Health average gross margin for 2022 was 66.85%, a 0.8% decline from 2021.
  • Guardant Health average gross margin for 2021 was 66.32%, a 2.1% increase from 2020.

Gross margin can be defined as a company's total sales revenue minus its cost of goods sold, divided by the total sales revenue, expressed as a percentage.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$147B
Gilead Sciences (GILD)$116B
Bristol Myers Squibb (BMY)$115.8B
Vertex Pharmaceuticals (VRTX)$110.2B
CSL (CSLLY)$81.9B
Regeneron Pharmaceuticals (REGN)$74.7B
GSK (GSK)$69.3B
Argenex SE (ARGX)$38.6B
Alnylam Pharmaceuticals (ALNY)$34.4B
BioNTech SE (BNTX)$27.6B
Illumina (ILMN)$22.3B
BeiGene (ONC)$21.7B
Biogen (BIIB)$20.8B
Moderna (MRNA)$14.8B
Insmed (INSM)$14B
Incyte (INCY)$13.9B
Genmab (GMAB)$13.9B
Genmab (GNMSF)$13.9B
Intra-Cellular Therapies (ITCI)$13.5B
Bio-Techne Corp (TECH)$12.5B
BioMarin Pharmaceutical (BMRN)$11.8B
Sarepta Therapeutics (SRPT)$11.1B
Vaxcyte (PCVX)$10.8B
QIAGEN (QGEN)$10.8B
Exact Sciences (EXAS)$10.1B
Swedish Orphan Biovitrum (BIOVF)$10.1B
Bio-Rad Laboratories (BIO.B)$9.8B
Exelixis (EXEL)$9.4B
Repligen (RGEN)$9.3B
Roivant Sciences (ROIV)$8.1B